Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

DiMe Generated Content

Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials

DiMe Research Committee working group discusses key considerations for generating evidence for clinical validity, regulatory pathways through which clinical validity evidence may be reviewed, and challenges that investigators may encounter while dealing with data from biometric monitoring technologies.


Recommendations for Defining and Reporting Adherence Measured by Miometric Monitoring Technologies: Systematic Review

DiMe Research Committee working group reviews methods and definitions by which adherence has been captured and reported using BioMets in order to identify gaps and provide recommendations to the field.

July 28, 2022

Considerations for Conducting Bring Your Own “Device” (BYOD) Clinical Studies

DiMe Research Committee working group explores the potential, risks, and key considerations for organizations to consider when using a “BYOD” approach in clinical research

July 28, 2022

Industry Voices—Virtual care should address transition points in our fragmented system

In partnership with IMPACT member Wellinks, DiMe leadership discuss how virtual-first care can improve patient experience and engagement across the care journey and optimize handoffs between care settings

July 27, 2022

Your Guide To Harnessing Clinical Trial Sensor Data Better

DiMe CEO, Jen Goldsack, describes the imperative for preparing for the use of sensor data at scale

July 26, 2022

New Toolkit Aims to Support Effective Virtual-First Care Transitions

The Digital Medicine Society and American Telemedicine Association have developed a new toolkit to support the integration of virtual and in-person healthcare.

June 28, 2022

FDA Diversity Plan Clinical Trials

A letter submitted on behalf of the Digital Medicine Society (DiMe) for consideration by the U.S. Food and Drug Administration (FDA) regarding Docket No. FDA-2021-D-0789 for “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability .”

June 2022

View DiMe Comment

Sign up to receive our monthly updates

Engage with the dime community on slack

USING A DIME RESOURCE? Share your story

Contact Us

Copyright ©2023 The Digital Medicine Society (DiMe). All Rights Reserved.